CMRF44+ dendritic cells from peripheral blood stem cell harvests of patients with myeloma as potential cellular vectors for idiotype vaccination.
D000911:Antibodies, Monoclonal / Q000378:metabolism*; D018952:Antigens, CD34 / Q000096:biosynthesis; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D019921:Biotinylation; D019496:Cancer Vaccines; D003520:Cyclophosphamide / Q000627:therapeutic use; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology / Q000378:metabolism*; D004705:Endocytosis; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D007963:Leukocytes, Mononuclear / Q000276:immunology; D009101:Multiple Myeloma / Q000276:immunology*; D010641:Phenotype; D013234:Stem Cells / Q000276:immunology*; D013997:Time Factors
D000911:Antibodies, Monoclonal; D018952:Antigens, CD34; D018906:Antineoplastic Agents, Alkylating; C474761:CMRF-44 monoclonal antibody; D019496:Cancer Vaccines; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide